Non-small cell lung cancer · line 1 · Atezolizumab adjuvant (resected NSCLC, 1 year)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ATEZO-ADJUVANT-NSCLC |
| ID | IND-NSCLC-ADJUVANT-ATEZO-PDL1POS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-07 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-IMPOWER-010-FELIP-2021 |
Notes
PD-L1 assay note: IMpower010 used the SP142 assay (Ventana). The SP142 clone is NOT interchangeable with 22C3 TPS (used for pembrolizumab). A patient PD-L1 result must be specifically tested with the SP142 assay for eligibility determination per this indication. Stage IB eligibility restricted to tumours ≥4 cm per protocol (not all IB tumours). OS not yet mature at primary analysis (32.2 month median follow-up); longer follow-up data awaited. Algorithm routing to this indication is out of scope for this chunk — see D-prefix algorithm extension work.
Used By
Algorithms
ALGO-NSCLC-ADJUVANT- ALGO-NSCLC-ADJUVANT